RiboTargets Competitors

At SCYNEXIS, we are committed to improving outcomes for patients living with severe, progressive, and underserved rare diseases. Around the world, patients with severe, progressive rare diseases continue to face limited therapeutic options and significant unmet medical need, creating meaningful opportunity for differentiated innovation. We are focused on advancing a portfolio of highly differentiated, clinical‑stage assets targeting the underlying biology of severe rare diseases. Our programs are designed around the needs of patients facing limited options, with a focus on delivering clinically meaningful benefit. Guided by deep scientific expertise and disciplined drug development execution, we strive to improve outcomes for patients who urgently need better solutions. (NASDAQ: SCYX)

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.

Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50.